EyePoint, Inc.
EYPTNasdaq
$13.30
↑ +2.0%Jul 17 close · end-of-day
Price
1Y↑ +32.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.1M
Enterprise Value
-$221.4M
P/E
—
P/S
0.2
P/B
0.0
EV/EBITDA
—
PEG
—
FCF Yield
-23740.4%
Dividend Yield
—
Revenue (TTM)
$7.6M
Net Income (TTM)
-$271.6M
Free Cash Flow (TTM)
-$271.5M
Gross Margin
—
Operating Margin
-3701.4%
Net Margin
-3567.1%
ROE
-117.8%
ROIC
-2808.6%
Debt / Equity
—
Net Cash
$222.5M
Return 1Y
+29.1%
Company profile
EyePoint Pharmaceuticals, Inc. provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema. DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the. treatment of wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion.
- CEO
- Nancy S. Lurker
- Sector
- Manufacturing
- Industry
- Measuring And Control Equipment
- Employees
- 120
- Headquarters
- Massachusetts
- Website
- eyepointpharma.com
Management & directors
- Duker Jay S.President and CEO
- Ribeiro RamiroChief Medical Officer
- Elston GeorgeChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
EYPT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$696,000.00↓ -97.2%
Diluted EPS-$0.99↑ +52.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $34.4M | $36.9M | $41.4M | $46.0M | $43.3M | $31.4M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$37.3M | -$55.3M | -$99.6M | -$75.1M | -$145.9M | -$243.4M |
| Net income | -$45.4M | -$58.4M | -$102.3M | -$70.8M | -$130.9M | -$232.0M |
| Diluted EPS | — | -$2.03 | -$2.74 | -$1.82 | -$2.32 | -$3.17 |
| Operating cash flow | -$14.4M | -$50.1M | -$65.0M | $1.9M | -$126.2M | -$240.1M |
| Free cash flow | -$14.8M | -$50.3M | -$67.2M | -$1.6M | -$130.3M | -$243.4M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -108.3% | -149.6% | -240.6% | -163.1% | -337.1% | -776.0% |
| Net margin | -131.8% | -158.1% | -247.0% | -153.8% | -302.4% | -739.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.5M | $10.5M | $11.6M | $24.5M | $5.3M | $966,000.00 | $619,000.00 | $696,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$34.5M | -$32.7M | -$45.2M | -$48.8M | -$62.2M | -$62.0M | -$70.3M | -$87.2M |
| Net income | -$30.8M | -$29.4M | -$41.4M | -$45.2M | -$59.4M | -$59.7M | -$67.6M | -$84.8M |
| Diluted EPS | -$0.58 | -$0.54 | -$0.65 | -$0.65 | -$0.85 | -$0.85 | -$0.82 | -$0.99 |
| Operating cash flow | -$20.2M | -$39.0M | -$35.8M | -$53.1M | -$62.6M | -$59.4M | -$65.0M | -$80.5M |
| Free cash flow | -$21.1M | -$40.6M | -$36.2M | -$53.4M | -$63.8M | -$60.2M | -$66.0M | -$81.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -364.5% | -311.2% | -390.4% | -199.7% | -1166.8% | -6420.8% | -11364.3% | -12532.5% |
| Net margin | -325.3% | -279.0% | -357.3% | -184.8% | -1114.3% | -6183.4% | -10922.3% | -12188.5% |
Company news
Jul 16, 2026
Jul 13, 2026
Jul 7, 2026
May 26, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-10 | Duker Jay S.· President and CEO | Tax withholding | 8,059 | $14.72 | $118,628.48 | filing |
| 2026-07-10 | Duker Jay S.· President and CEO | Option exercise | 16,667 | $0.00 | $0.00 | filing |
| 2026-06-30 | Ribeiro Ramiro· Chief Medical Officer | Sale | 2,438 | $15.02 | $36,611.93 | filing |
| 2026-06-30 | Ribeiro Ramiro· Chief Medical Officer | Sale | 2,437 | $15.00 | $36,555.00 | filing |
| 2026-06-30 | Ribeiro Ramiro· Chief Medical Officer | Option exercise | 2,438 | $8.26 | $20,137.88 | filing |
| 2026-06-30 | Ribeiro Ramiro· Chief Medical Officer | Option exercise | 2,437 | $8.26 | $20,129.62 | filing |
| 2026-05-25 | Elston George· Chief Financial Officer | Tax withholding | 3,627 | $12.93 | $46,897.11 | filing |
| 2026-05-25 | Elston George· Chief Financial Officer | Option exercise | 7,500 | $0.00 | $0.00 | filing |
| 2026-04-17 | Ribeiro Ramiro· Chief Medical Officer | Sale | 2,437 | $15.00 | $36,555.00 | filing |
| 2026-04-17 | Ribeiro Ramiro· Chief Medical Officer | Option exercise | 2,437 | $8.26 | $20,129.62 | filing |
| 2026-03-23 | Duker Jay S.· President and CEO | J | 76,766 | $13.11 | $1.0M | filing |
| 2026-03-23 | Duker Jay S.· President and CEO | J | 76,766 | $13.11 | $1.0M | filing |
| 2026-03-16 | Duker Jay S.· President and CEO | Buy | 1,500 | $13.15 | $19,723.80 | filing |
| 2026-03-04 | Ribeiro Ramiro· Chief Medical Officer | Sale | 2,438 | $17.87 | $43,571.69 | filing |
| 2026-03-04 | Ribeiro Ramiro· Chief Medical Officer | Option exercise | 2,438 | $8.26 | $20,137.88 | filing |
| 2026-03-02 | Elston George· Chief Financial Officer | Gift | 5,000 | $0.00 | $0.00 | filing |
| 2026-03-02 | Elston George· Chief Financial Officer | Gift | 5,000 | $0.00 | $0.00 | filing |
| 2026-02-17 | Ribeiro Ramiro· Chief Medical Officer | Sale | 2,437 | $15.00 | $36,555.00 | filing |
| 2026-02-17 | Ribeiro Ramiro· Chief Medical Officer | Option exercise | 2,437 | $8.26 | $20,129.62 | filing |
| 2026-01-06 | Duker Jay S.· President and CEO | Tax withholding | 10,054 | $16.86 | $169,510.44 | filing |
| 2026-01-06 | Elston George· Chief Financial Officer | Tax withholding | 4,487 | $16.86 | $75,650.82 | filing |
| 2026-01-06 | Duker Jay S.· President and CEO | Option exercise | 20,793 | $0.00 | $0.00 | filing |
| 2026-01-06 | Lurker Nancy | Option exercise | 75,133 | $0.00 | $0.00 | filing |
| 2026-01-06 | Elston George· Chief Financial Officer | Option exercise | 15,285 | $0.00 | $0.00 | filing |
| 2026-01-05 | Ribeiro Ramiro· Chief Medical Officer | Sale | 42,544 | $17.10 | $727,319.46 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.